Hikma Pharmaceuticals PLC (HIK) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Before we start, I'd like to remind you that any forward-looking statements or projections made by HICMA during this call are made in good faith based on information currently available and are subject to risks and uncertainties that may cause actual results to differ materially from those projected. For further information, please see the Principal Risks and Uncertainties section in HICMA's latest annual report. And with that, I'll hand over to Riyadh for some opening remarks before we go to Q&A. Thank you very much. Good morning, everyone. Let me start by maybe a few words. Summarizing the half, the first half, I believe we had a strong half. We have a strong revenue growth of about 6%. That's driven by... Volume growth across all segments. All the segments are doing well, as expected. I think the big story and the most impressive part of it all is that we had revenue growth of 12% in the injectable division. Revenue growth means that we have good demand on our products, and that's very, to be honest, it's a good indication for us that All the investment that we're doing in expanding our facilities and increasing our capacity will all bring in good results, and that's happening as we speak today. And the growth is not happening in one region. We have 26% growth in Europe, and that's something also very impressive. MENA, 16%, and MENA has been doing this year on year for the past few years and continues to do so. And, of course, the U.S., we have a growth of 8%. That's all driven by new launches, driven by volume increases, and, of course, the Zellier portfolio that we had acquired middle of last year. The branded revenue is up 4%, and the branded division has been doing really well year on year with not only good growth but also very stable growth. margins, very st...